A U.S. judge’s ruling on Monday invalidating Allergan Plc's patents on its blockbuster $1.5 billion dry-eye medicine, Restasis, has cast doubt on the company's novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said.
- Johnson & Johnson wins reversal of $72 million verdict over talc cancer risks
- Trump's drug czar nominee withdraws from consideration |
- New cancer drugs help Johnson & Johnson top profit estimates
- China confirms bird flu outbreak at poultry farms in central province
- Florida needs more pet-friendly hurricane shelters for the elderly
(Reuters Health) - Sick or injured men who receive blood transfusions may be more likely to die if their donor was a woman who has been pregnant in the past, a new study suggests.
UnitedHealth Group Inc, the largest U.S. health insurer, said earnings will grow 13 to 16 percent in 2018 as medical costs remain low, and that it expects to benefit from new insurance products backed by U.S. President Donald Trump.
(Reuters Health) - Frail patients are more likely to have serious complications after elective outpatient surgery than people who are healthier and stronger, a recent study suggests.
Transenterix Inc's chief executive played down on Tuesday the threat posed by his company's surgical robotic system to market leader Intuitive Surgical Inc, saying he did not expect the two to compete head on.